Asset Details
Do you wish to reserve the book?
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction
Do you wish to request the book?
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction
2008
Overview
The bradycardic agent ivabradine has proved to be of benefit in experimental models with the end points of ischaemic myocardial blood flow and contractile function, infarct size, post‐infarct remodelling and atherosclerosis. The benefits to ischaemic myocardial blood flow and contractile function are strictly heart rate dependent; those on infarct size are partly heart rate independent. The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post‐infarct remodelling is entirely unclear. British Journal of Pharmacology (2008) 155, 970–971; doi:10.1038/bjp.2008.347; published online 1 September 2008
Publisher
Blackwell Publishing Ltd,Nature Publishing Group
Subject
/ Atherosclerosis - drug therapy
/ Atherosclerosis - physiopathology
/ Cardiotonic Agents - pharmacology
/ Humans
/ Myocardial Infarction - drug therapy
/ Myocardial Infarction - physiopathology
/ Myocardial Reperfusion Injury - drug therapy
/ Myocardial Reperfusion Injury - physiopathology
